Karen L Reckamp

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer
    Karen L Reckamp
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Clin Cancer Res 12:3381-8. 2006
  2. pmc Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis
    Judong Pan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer 5:56. 2006
  3. doi request reprint Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance
    Kostyantyn Krysan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Thorac Oncol 3:107-10. 2008
  4. ncbi request reprint Inflammation and lung carcinogenesis: applying findings in prevention and treatment
    Katherine A Peebles
    David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, UCLA Lung Cancer Research Program, CA, USA
    Expert Rev Anticancer Ther 7:1405-21. 2007
  5. ncbi request reprint Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma
    Seok Chul Yang
    Department of Medicine, Lung Cancer Research Program, University of California at Los Angeles, CA 90095 1960, USA
    Cancer Res 66:3205-13. 2006
  6. ncbi request reprint Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner
    Kostyantyn Krysan
    UCLA Lung Cancer Research Program of Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1690, USA
    Cancer Res 65:6275-81. 2005
  7. doi request reprint Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin
    Karen L Reckamp
    Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, California, USA
    J Thorac Oncol 3:117-24. 2008
  8. ncbi request reprint The potential and rationale for COX-2 inhibitors in lung cancer
    Kostyantyn Krysan
    David Geffen School of Medicine at UCLA, Lung Cancer Research Program, 37 131 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095 1690, USA
    Anticancer Agents Med Chem 6:209-20. 2006

Collaborators

Detail Information

Publications8

  1. ncbi request reprint A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer
    Karen L Reckamp
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Clin Cancer Res 12:3381-8. 2006
    ....
  2. pmc Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis
    Judong Pan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer 5:56. 2006
    ..Therefore, our data suggest that the CXCL12/CXCR4 biological axis plays an important role in regulating the organ-specific metastasis of RCC...
  3. doi request reprint Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance
    Kostyantyn Krysan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Thorac Oncol 3:107-10. 2008
    ..Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors...
  4. ncbi request reprint Inflammation and lung carcinogenesis: applying findings in prevention and treatment
    Katherine A Peebles
    David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, UCLA Lung Cancer Research Program, CA, USA
    Expert Rev Anticancer Ther 7:1405-21. 2007
    ..These newly discovered molecular mechanisms in the pathogenesis of lung cancer provide novel opportunities for targeted therapy and prevention in lung cancer...
  5. ncbi request reprint Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma
    Seok Chul Yang
    Department of Medicine, Lung Cancer Research Program, University of California at Los Angeles, CA 90095 1960, USA
    Cancer Res 66:3205-13. 2006
    ....
  6. ncbi request reprint Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner
    Kostyantyn Krysan
    UCLA Lung Cancer Research Program of Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1690, USA
    Cancer Res 65:6275-81. 2005
    ..Importantly, these findings suggest that COX-2 overexpression may contribute to EGFR inhibitor resistance in NSCLC...
  7. doi request reprint Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin
    Karen L Reckamp
    Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, California, USA
    J Thorac Oncol 3:117-24. 2008
    ..Markers of EMT and tumor invasion were evaluated in patient serum from a phase I clinical trial investigating the combination of celecoxib and erlotinib in non-small cell lung cancer (NSCLC) patients...
  8. ncbi request reprint The potential and rationale for COX-2 inhibitors in lung cancer
    Kostyantyn Krysan
    David Geffen School of Medicine at UCLA, Lung Cancer Research Program, 37 131 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095 1690, USA
    Anticancer Agents Med Chem 6:209-20. 2006
    ....